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OUTCOMES OF MANAGEMENT OF RETAINED HEMOTHORAX 
SAMUEL WING 
ABSTRACT 
Purpose: Hemothorax, the collection of blood in the intrapleural space, commonly 
arises in patients suffering from thoracic trauma. Fluid collections in this space can 
compromise cardiac and respiratory function and if left untreated, can result in 
hypovolemic crisis. Fluid is often successfully drained via a tube thoracostomy, in 
which an intercostal drain is inserted into the pleural space. If residual blood 
remains, however, clotting may occur and result in a retained hemothorax (RH). 
Intrapleural administration of tissue plasminogen activator (tPA), a fibrinolytic drug 
typically utilized in ischemic stroke, has been shown to be both a safe and effective 
technique to hydrolyze RH clots and reduce the need for more invasive surgical 
interventions. The present study aims to evaluate the safety and efficacy of tPA 
administration at Boston Medical Center (BMC) and compare this data to those of 
prior studies. This study will also investigate if tPA as a definitive treatment for RH, 
could reduce the need for additional interventions such as surgical procedures 
including Video-Assisted Thoracoscopic Surgery (VATS) and/or invasive 
thoracaotomy. Hospital/intensive care unit (ICU) lengths of stay (LOS), ventilator 
time, and complication rates will be used to determine if tPA may allow for a 
significant decrease in patient cost and burden of care versus surgery. An analysis 
of patient demographics and injury data will be used to determine the individual 
factors that could be used to predict the success of tPA as a definitive treatment. 
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Using evidence-based treatment protocols, the aforementioned data will be 
critically evaluated to determine the appropriate timing and sequential positioning 
of tPA administration in the treatment algorithm for retained hemothorax. 
 
Methods: A single-institution retrospective chart review was conducted of patients 
treated for traumatic pneumohemothorax by the Department of Acute Care and 
Trauma Surgery at Boston Medical Center. A study on predictive factors of the 
development of retained hemothorax included all such patients that presented to 
the emergency department (ED) between May 2014 and June 2016. Demographic 
and injury characteristics were analyzed to determine if patients from specific 
groups or with specific injuries are more prone to develop RH. To evaluate the 
safety of intrapleural tissue plasminogen activator, the incidence of complications 
such as post-trauma infection and mortality were determined in patients that were 
administered tPA to resolve retained hemothorax between May 2014 through 
December 2016. Next, utilizing an expanded data set, the efficacy of tPA was 
evaluated by determining the percentage of cases in which tPA was able to 
definitively resolve RH. Secondary efficacy data including average hospital length 
of stay, average ICU length of stay, average mechanical ventilation time, and rate 
of readmission were compared between various interventions as well. Finally, to 
elucidate the risk factors for RH and independent predictors of tPA as a definitive 
treatment, demographic data including age, ethnicity, and gender as well as injury 
data including mechanism of injury, the presence or absence of multisystem 
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trauma, and the presence or absence of specific injuries such as rib fracture, 
pulmonary contusion, or diaphragmic insult were collected. 
 
Results: A statistically significant positive correlation was observed between the 
likelihood of developing RH and both abdominal alimentary tract and extremity 
injuries, indicating that these injuries may serve as predictive factors for RH 
development. In a study investigating the safety of intrapleural tPA, there was no 
statistically significant difference in post-trauma infection rates between individuals 
treated with tPA and those who were not. Additionally, tPA treatment was 
associated with a lower mortality rate. Efficacy studies revealed that tPA therapy 
was associated with a statistically significant decrease in mechanical ventilation 
time, as compared to surgical intervention, however, tPA carried a RH resolution 
rate of just 43% with one patient experiencing a major adverse systemic reaction 
to the drug. Finally, demographic and injury data were analyzed to determine 
predictive factors of tPA success, but no statistically significant relationships were 
observed between any of these characteristics and the outcome of tPA therapy. 
 
Conclusion: Intrapleural tPA is a safe and effective alternative to more invasive 
surgical procedures. The success rate of tPA therapy in the present study was less 
than previous studies have indicated, however, the potential decreased ventilation 
time is important for preventing ventilator associated pneumonia (VAP) and the 
high rate of mortality it carries. Although the success rate is lower than expected, 
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tPA should still be considered in the RH treatment protocol, prior to surgery, to 
decrease required ventilation time and potentially prevent the need for more 
invasive interventions with higher costs, morbidity, mortality rates, and patient 
burden. 
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INTRODUCTION 
 
THORACIC TRAUMA 
Identification and stabilization of life-threatening injuries in an expeditious 
and definitive manner is the primary concern of the critical care surgeon. 
Implementation of this skill set is particularly important for the management of 
thoracic injuries, in which cardiac and pulmonary compromise are distinct 
possibilities. Trauma data from the United Kingdom has suggested that 
approximately 25% of trauma deaths are directly attributable to thoracic injuries, 
complicated by their highly heterogenous presentation. Penetrating injuries such 
as gunshot or stab wounds can cause cardiovascular compromise from laceration 
of the heart, aorta, or other prominent thoracic vessels and pulmonary compromise 
from disruption of the airway, lungs, or diaphragm. The compression and shear 
forces associated with blunt injuries, such as those from motor vehicle collisions, 
may cause multiple rib fractures, flail chest, and extensive multi-system organ 
damage which is often more difficult to identify and diagnose [Figure 1.]. Thoracic 
injuries from both blunt and penetrating mechanisms are particularly life-
threatening when they cause decreased alveolar gas exchange, hypovolemia 
(reduced blood volume from active hemorrhage), or decreased cardiac output, 
which together coalesce in hypoxia (inadequate oxygenation) of vital organs such 
as the heart and brain. Prompt imaging, diagnosis, and delivery of interventions 
aimed at the restoration of proper lung and heart function, cessation of internal 
bleeding, and maintenance of adequate organ perfusion and oxygenation, 
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significantly increases the chance of survival for the thoracic trauma patient (Blyth 
2014). 
 
 
Figure 1. Common Thoracic Injuries Caused by Blunt and Penetrating 
Mechanisms 
This table from Thoracic Trauma by Andrew Blyth provides examples of common 
injuries that result from both penetrating and blunt trauma to the chest. Penetrating 
injuries typically cause direct injury to tissues while blunt injuries may cause 
damage to multiple tissue layers and organ systems from associated forces (Blyth 
2014). 
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HEMOTHORAX 
A hemothorax, the collection of fluid within the pleural space, is a common 
surgical emergency with approximately 300,000 cases per year in the United 
States alone (Boersma et al. 2010, Richardson et al. 1996). Hemothoraces may 
result from spontaneous or iatrogenic causes such as the rupture or accidental 
disruption of the visceral pleura of the lung due to pleural adhesions or during 
cardiopulmonary surgery, respectively (Baumann et al. 2001, Yeam & Sassoon 
1997). Thoracic trauma, however, is the most common cause of hemothorax, 
occurring in approximately 38% of patients with thoracic injuries (Al-Koudmani et 
al. 2012). A traumatic hemothorax arises when injuries, such as penetrating 
wounds from projectiles or rib fractures from blunt impact, injure the pulmonary 
parenchyma or thoracic vasculature, causing accumulation of blood in the pleural 
cavity (Boersma et al. 2010). Excess fluid between the visceral pleura of the lung 
and the parietal pleura of the thoracic wall can result in impaired lung inflation, 
diminished respiratory function, and pulmonary vascular shunting (Blyth 2014) 
[Figures 2 & 3.]. 
If the hemothorax is left untreated, blood loss of one-third total volume may 
result in a massive hemothorax and subsequent hypovolemic shock (Blyth 2014). 
The primary first-line intervention for a traumatic hemothorax is a tube 
thoracostomy, in which a large-bore chest tube (28 French or larger) is inserted in 
the fourth or fifth intercostal space to drain excess fluid from the pleural cavity 
[Figure 4.]. This procedure is indicated in all hemothorax patients without an aortic 
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dissection or rupture (Blyth 2014, Mowery et al. 2011). Drainage of intrapleural 
fluid through a chest tube is typically a highly successful definitive treatment for 
hemothorax with as many as 85% of patients not requiring further surgical 
intervention (Mattox et al. 1996).  
 
 
Figure 2. Pleural Space Anatomy  
This illustration from Pleural Space Anatomy by Charalampos Charalampidis et al. 
shows the tissue layers that comprise the pleural space. The pleural space is a 
potential cavity between the superficial-most layer of the lung, the visceral pleura 
and the deep-most layer of the thoracic wall, the parietal pleura. Injury to either or 
both layers may result in a pneumothorax or hemothorax, which are the 
accumulation of air or blood in the pleural space, respectively (Charalampidis et 
al. 2015). 
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Figure 3. Radiologic Presentation of Patients With and Without Hemothorax 
From Indicators of haemothorax in patients with spontaneous pneumothorax by 
Hsu et al. A. The white opacity shown inferior to the patient’s left lung represents 
a hemothorax. This blood infiltration results in an apparent reduction in left 
pulmonary volume and decreased ventilation. B. This radiograph shows a patient 
without a hemothorax with normal lung volume. 
 
 
Figure 4. Radiologic Appearance of Intercostal Thoracostomy Tube  
From Phrenic arterial injury presenting as delayed hemothorax complicating 
simple rib fracture by Ahn et al. The black arrows above show the path of an 
intercostal thoracostomy tube used to drain fluid and air collections from the pleural 
space. The tube was inserted laterally through the axilla and runs apical to the 
patient’s right lung. 
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RETAINED HEMOTHORAX 
Although tube thoracostomy is a widely accepted practice, various 
complications can arise including misplacement of the tube, laceration of thoracic 
vessels, pulmonary or cardiac injury, empyema (infection of the pleural cavity), or 
blockage of the chest tube from clotted blood (Sethuraman et al. 2011). Retained 
hemothorax (RH), occurring in anywhere between 5-30% of hemothorax patients, 
results when intrapleural blood clots form, occlude the chest tube, impede 
drainage, and pose an increased risk of infectious complications (Heniford et al. 
1997, Menger et al. 2012). In a multi-center study by the American Association for 
the Surgery of Trauma (AAST), among patients with retained hemothorax, 
approximately one fifth of cases were complicated by pneumonia (infection of the 
lung alveoli) and approximately one fourth of cases were complicated by empyema 
(Dubose et al. 2012). Another study by Eren et al. concluded that patients with 
retained hemothorax have at a 5.5-fold higher risk of empyema than those without 
retained intrapleural fluid accumulations (Eren et al. 2008). Additionally, when 
blood is exposed to the agitative motion of the diaphragm and lungs, further clotting 
may occur. If these clots are not fully hydrolyzed by pleural enzymes or if bleeding 
persists and overwhelms the capacity of enzymatic activity, these clots may 
aggregate, attach to the lungs, and form strong adhesions. These adhesions are 
highly difficult to remove and further hinder respiratory mechanics, a condition 
known as trapped lung (Boersma et al. 2010). 
 7 
SURGICAL INTERVENTIONS FOR RETAINED HEMOTHORAX 
In cases of insufficient drainage, pervasive bleeding, or hemodynamic 
instability, a thoracotomy (incision into the thoracic cavity), may be performed to 
locate and repair sources of hemorrhage, remove fibrous clots, and decorticate 
thoracic soft tissue (Yeam et al. 1997, Blyth 2014). Surgical thoracotomy is the 
most successful definitive treatment for retained hemothorax particularly among 
patients sustaining a diaphragmic injury, those with a hemothorax larger than 900 
cc, and individuals initially given bilateral chest tubes to treat a multi-focal 
hemothorax. It is estimated that approximately 10% of patients with a simple 
hemothorax and 22.2% of patients with a retained hemothorax will ultimately 
require a surgical thoracotomy (Dubose et al. 2012, Lowdermilk & Naunheim 
2000). Although this procedure provides the clearest view to access and address 
the source of bleeding, it is highly invasive and carries a high rate of mortality, 
especially if performed outside of a formal operative setting (Blyth 2014) [Figure 
6.]. 
Video-Assisted Thoracoscopic Surgery (VATS), a far less invasive 
technique, similar to laproscopy, utilizes the placement of a camera and surgical 
instruments through a series of small incisions to access the thoracic cavity, stop 
bleeding, evacuate clots, and break down adhesions (Goodman et al. 2013, Ali et 
al. 2008) [Figure 5.]. VATS has been proven to be safe for the monitoring and 
treatment of acute and chronic thoracic trauma and is the gold standard in most 
modern treatment algorithms for the removal of intrapleural fluid. VATS is typically 
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utilized in hemodynamically stable patients with acute blood loss and has found to 
be particularly successful in patients without diaphragmic injuries and those with a 
hemothorax smaller than 900 cc (Ali et al. 2008, Dubose et al. 2012). Although it 
is the most commonly utilized intervention used in the treatment of RH, with 
approximately one third of patients undergoing VATS, it is contraindicated in a 
variety of patients including those with severe adhesions, heart or great vessel 
injury, and hemodynamic instability. Additionally, VATS requires single-lung 
ventilation and may not be safely tolerated in patients with chronic respiratory 
conditions or pulmonary compromise (Dubose et al. 2012, Goodman et al. 2013). 
Although successful, both thoracotomy and VATS are invasive operations and are 
associated with significant pain and financial burden for the patient (Landreneau 
et al. 1996, Velmahos & Demetriades 1999).  
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Figure 5. Illustration of Video-Assisted Thoracoscopic Surgery 
Instrumentation 
From Cancer Research UK. In a Video-Assisted Thoracoscopic Surgery, small 
ports are introduced to the chest wall via multiple small incisions. A camera is 
placed through one port to facilitate diagnosis and provide an internal view of the 
thoracic cavity to guide the proper placement of surgical instruments for repair of 
damaged tissue.  
 
 
Figure 6. Surgical Thoracotomy Performed in the Emergency Room 
From Emergency department thoracotomy for the critically injured patient: 
Objectives, indications, and outcomes by Cothren & Moore. In a surgical 
thoracotomy, a lateral incision is made to the thorax to gain access to intrathoracic 
organs. A Finochietto retractor, indicated by the black arrows above, is used to 
spread the ribs and increase the size of the intercostal surgical window. With the 
high morbidity and mortality rate it carries, thoracotomies are best performed in a 
formal operating setting but may be performed in the emergency department in 
instances of severe hemodynamic instability. 
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NON-SURGICAL INTERVENTIONS FOR RETAINED HEMOTHORAX 
With the instability of polytrauma patients, the critical care surgeon must 
carefully weigh the risks and benefits of various interventions and consider the 
possibility that highly invasive techniques may cause further injury. As a result, 
non-surgical techniques such as close monitoring and observation of the patient, 
placement of an additional thoracostomy tube or image-guided catheter drain, and 
administration of intrapleural finbrinolytic drugs should be considered (Dubose et 
al. 2012). Since the natural course of retained hemothorax has yet to be 
elucidated, observation alone remains a viable treatment option and may prevent 
unnecessary complications from occurring. Observation has shown to be 
particularly successful in patients with smaller hemothoraces (<300 cc) and 
individuals that are less likely to tolerate surgery such as the elderly and those with 
severe abdominal injuries and multiple rib fractures (Dubose et al. 2012). To 
facilitate further drainage, a second thoracostomy tube may be placed under 
radiological guidance. The placement of additional tubes is found to be more 
successful in patients with small hemothoraces and in individuals who had a 
pneumothorax as the indication for their initial tube placement. Although there is a 
risk of injuring the thoracic soft tissue when placing additional catheters, the risk is 
far less than that associated with both thoracotomy and VATS (Dubose et al. 
2012). In cases of persistent blood clotting and tube occlusion, intrapleural 
fibrinolytics including streptokinase and urokinase can be administered through the 
chest tube to hydrolyze clots and reestablish flow out of the tube. Intrapleural 
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finbrinolytics, as a definitive treatment, have been shown to be significantly 
cheaper than VATS costing on average $19,431 less for streptokinase and 
$19,152 less for urokinase per hospital stay (Kimbrell et al. 2007). Additionally, 
prior studies by Moulton et al., Jerjes-Sanchez et al., Iuci et al., and Kimbrell et al. 
have shown that intrapleural urokinase and streptokinase administration can serve 
as a safe and effective non-operative treatment, demonstrating full resolution of 
retained hemothorax in 93.8%, 91.7%, 91.6% and 93% of patients, respectively 
(Moulton et al. 1989, Jerjes-Sanchez et al. 1996, Iuci et al. 1998, Kimbrell et al. 
2007). There is a persistent debate, however, about the true efficacy of 
fibrinolytics, as the aforementioned studies all had very small patient sample sizes 
and other investigations such as that by Oğuzkaya et al. show that VATS as a 
definitive treatment was significantly more effective than streptokinase for lowering 
hospital length of stay and mitigating the need for surgical thoracotomy (Oğuzkaya 
et al. 2005). 
 
TISSUE PLASMINOGEN ACTIVATOR 
Tissue plasminogen activator (tPA), a human-derived fibrinolytic, is a safer 
alternative to streptokinase and urokinase. Commonly used in the treatment of 
ischemic stroke, tPA is a serine protease that acts to stimulate clot breakdown 
machinery (Deb et al. 2010) [Figure 7.] Like other fibrinolytics, in cases of retained 
hemothorax, tPA can be used to break down clots and adhesions within the pleural 
space and the chest tube itself to achieve proper drainage of intrapleural fluid 
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collections (Boersma et al. 2010). tPA is administered through a chest tube or an 
image-guided catheter drain and thus is a far less invasive intervention than either 
thoracotomy or VATS (Dubose et al. 2012). This route of administration may allow 
for higher levels of patient tolerence, mitigate cost, and prevent inadvertent tissue 
damage from surgery (Blyth 2014). Since tPA is a relatively recent treatment 
modality for retained hemothorax, very few studies have sought to investigate the 
safety and efficacy of this drug in depth. Studies by Ahmed et al., Skeete et al., 
Ben-Or et al., and Zuckerman et al. have suggested that fibrinolytics are safe for 
various pleural pathologies such as empyema, loculated pleural effusion, 
parapneumonic effusion, and simple hemothorax, respectively (Ahmed & Yacoub 
2010, Skeete et al. 2004, Ben-Or et al. 2011, Zuckerman et al. 2009). On the 
contrary, the largest comparative efficacy study of retained hemothorax 
interventions, conducted by the AAST, concluded that tPA use was both infrequent 
(used as the initial treatment in 4.6% of cases) and ineffective (66.7% of patients 
required additional interventions) (Dubose et al. 2012). Finally, there is very limited 
data about potential adverse effects of tPA. If administered in large enough doses, 
tPA may exhibit a systemic effect and in one specific case, tPA was shown to 
cause hematuria, necessitating a blood transfusion (Skeete et al. 2004). 
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Figure 7. Finbrinolytic Mechanism of Tissue Plasminogen Activator 
From Cathflo Alteplase: http://www.cathflo.com/moa/. Tissue plasminogen 
activator (tPA) exhibits its fibrinolytic behavior through the activation of 
plasminogen. tPA binds to fibrin clots, frees plasminogen enzyme bound within the 
fibrin, and converts the enzyme to plasmin which in turn hydrolyzes fibrin and 
dissolves the clot.  
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EVIDENCE-BASED TREATMENT ALGORITHM 
The heterogenous nature of thoracic trauma, variability in the presentation 
of hemothorax, institutional resources, provider training, diagnostic techniques, 
and patient demographics have made the development of a comprehensive 
treatment algorithm for retained hemothorax exceedingly difficult. Surgeons have 
typically made treatment recommendations based off subjective criteria, such as 
their individual interpretation of x-ray images and, until recently, no comprehensive 
strategy existed to use concrete clinical data to guide treatment decisions (Mowery 
et al. 2011). In a study by Dennis et al., an evidence-based treatment algorithm 
was implemented and a pre- vs. post-implementation retrospective study was 
conducted to determine its effect on treatment decisions [Figure 8.]. This study 
found that use of an evidence-based algorithm reduced the number of 
unnecessary interventions and increased the utilization rate of minimally invasive 
techniques over surgical approaches (Dennis et al. 2017). With these evidence-
based algorithms in mind, data from the present study will be critically evaluated 
to suggest the appropriate timing and sequential position of tPA administration in 
the retained hemothorax treatment algorithm.  
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Figure 8. Evidence-Based Treatment Algorithm for Simple and Retained 
Hemothorax 
From Use of an evidence-based algorithm for patients with traumatic hemothorax 
reduces need for additional interventions by Dennis et al. The above diagram 
represents a proposed treatment algorithm for the management of traumatic 
hemothorax. A tube thoracostomy is performed to drain the hemothorax and 
resolution is assessed by observing decreased pleural space opacity on chest x-
ray. An additional thoracostomy tube is the initial secondary intervention for a non-
improving or worsening hemothorax. If the hemothorax is larger than 300 mL after 
three treatment days, the patient’s ability to tolerate surgical intervention is 
assessed. If the patient is able to tolerate surgery, they will undergo VATS and if 
unable to tolerate surgery, the patient will begin a regimen of intrapleural fibrinolytic 
therapy (tPA) (Dennis et al. 2017). 
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SPECIFIC AIMS 
 
The present study aims to use data from patients treated with tPA, 
thoracotomy, and VATS at Boston Medical Center, an American College of 
Surgeons verified level 1 trauma center, to conduct a comparative efficacy study 
and investigate if tPA as a definitive treatment could reduce the need for additional 
interventions. Additionally, demographic and injury data from these patients will be 
used to identify specific determinants that can be used to predict tPA as a 
successful definitive intervention. The following aims will be addressed: 
 
Aim 1: Identify demographic and injury factors that could be used to predict the 
development of a retained hemothorax.  
 
Aim 2: Determine the safety of tPA in treating retained hemothorax by comparing 
complication rates of RH patients who received tPA to that of RH patients who did 
not receive tPA. 
 
Aim 3: Evaluate the outcomes of RH patients treated with intrapleural tPA and 
determine its rate of success as a definitive treatment. 
 
Aim 4: Conduct a comparative efficacy analysis of tPA versus surgical 
interventions (VATS and surgical thoracotomy) in successfully resolving retained 
hemothorax. Hospital/ICU LOS data, tube thoracostomy drainage time data, and 
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mechanical ventilation timeline data will be used to compare the patient burden 
associated with each therapy. 
 
Aim 5: Utilize demographic data and injury data including mechanism of injury, 
injury severity, and injury types to identify factors that could predict if tPA will be 
successful as a definitive intervention for RH in specific patients. 
 
Aim 6: Assess the aforementioned data to determine the appropriate sequential 
position of tPA fibrinolytic therapy in the RH treatment algorithm. 
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METHODS 
 
STUDY DESIGN 
 This study was a retrospective, single-institution study of patients 
presenting to the emergency department of Boston Medical Center (BMC) with a 
pneumohemothorax. BMC, an American College of Surgeons verified level I 
trauma center, is the busiest trauma and emergency services center in New 
England and thus serves a large population of patients with thoracic trauma. A 
retrospective chart review was performed to collect demographic, injury, 
intervention, and outcomes data. 
 
PATIENT SELECTION 
 This study included various samples of patients treated for 
pneumohemothorax between 2013 and 2016. The outcomes investigation utilized 
data from the full date range while the safety, efficacy, and predictors of tPA 
success studies utilized data from May 2014 through December 2016 and the 
predictors of RH development study utilized data from May 2014 through June 
2016. May 2014 was chosen as the start point for these studies because BMC 
underwent a transition to the EPIC charting system at that time and patient data 
prior to this date were submitted via a different EMR system. The two-year study 
period length allowed for feasibility of analysis while still providing a representative 
cross-section of the BMC patient population from different ages, ethnicities, and 
with different injury types and comorbidities. Additionally, the selected study 
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periods were of appropriate lengths for ensuring that no major changes in provider 
training or treatment protocols occurred during the timeframe, causing the addition 
confounding variables. Patients of all ages, genders, races, and ethnicities were 
selected.  
 
DATA COLLECTION 
 A data collection form was utilized to extract data points of interest from 
patient charts [Appendix]. The form was divided into the five constituent 
categories including demographic data, injury presentation data, injury type data, 
intervention data, and outcomes data. Measured demographic variables included 
age, race and ethnicity, gender, and comorbidities from prior medical history. Injury 
presentation data included cause of injury, mechanism of injury (blunt vs. 
penetrating), and Injury Severity Scale (ISS). To calculate ISS, an Abbreviated 
Injury Scale (AIS) score on a scale of 1 to 6 was assigned to six major body regions 
including the head and neck, face, chest, abdomen, extremity, and external. The 
ISS is the sum of the squared AIS values of the three most injured regions. Data 
on injury types consisted of the presence or absence of multisystem trauma, 
disruption or pseudoaneurysm of aorta or other great vessel, respiratory failure, rib 
fracture, flail chest, pulmonary contusion or brain, spinal, lung, heart, diaphragm, 
vascular, esophageal, spleen, liver, abdominal alimentary tract, kidney, extremity, 
or other orthopedic injury. Data on the presence or absence of the aforementioned 
injury types were used to determine if certain injuries may result in a higher rate of 
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progression to retained hemothorax or serve as contraindications for tPA 
fibrinolytic intervention. For patients with retained hemothorax, data on the percent 
of patients receiving tPA, its timing, and dose were utilized to determine the rate 
of success of fibrinolytic therapy and optimal treatment parameters. The rate of 
success of tPA in definitively treating RH was directly compared to that of 
additional surgical procedures, namely VATS. Finally, outcomes data including 
total tube drainage days, ventilator days, ICU LOS, hospital LOS, and the presence 
or absence of complications including infection and mortality, were collected to 
assess whether certain interventions have a significant effect on patient burden, 
morbidity, and mortality. 
 
NOTICE OF PATIENT CONFIDENTIALITY 
 Data was collected directly from patient care records from encounters at 
BMC. The study was retrospective in nature, utilizing data solely from the BMC 
clinical database, and collected with a waiver of consent because this human 
subjects study was exempted from the consent requirement by the Institutional 
Review Board (IRB #H-34977) Nevertheless, extensive measures were taken to 
uphold privacy and ensure patient confidentiality. Once candidates for the study 
were identified, a master key listing patient medical record numbers was generated 
and stored in a locked office separate from all collected data. The data collected 
from the chart review was stored on an encrypted flash storage drive and all files 
shared among researchers were password protected. 
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STATISICAL ANALYSIS 
 To determine if independent demographic characteristics and/or injury 
mechanisms, levels of severity, or types correlate with an increased chance of 
developing a retained hemothorax, a multivariate chi-squared analysis was 
performed. Pearson’s chi-square test of significance was used for analysis of 
variables with a sufficient patient sample size while Fisher’s exact test was used 
in cases where more than 25% of cells had less than 5 correspondents. A 
likelihood ratio was used as the test of significance for cases where the chi-
squared table was larger than 2 by 2 [Table 1.]. This same framework was applied 
to determine if demographic and injury data could be used to predict the success 
of tPA as a definitive treatment for retained hemothorax [Table 5.]. 
 To evaluate the safety of tPA as a treatment for RH, a MANOVA was 
performed to determine if patients that received tPA had a similar rate of 
complications (post-trauma infection, positive sputum culture, positive blood 
culture, empyema, and mortality) to that of patients who did not receive tPA. 
Levene’s test of equality of error variances was used to calculate the significance 
of the relationship between treatment type and post-treatment complications 
[Table 3.]. This same framework was applied to determine the efficacy of tPA as 
a definitive RH intervention versus surgery. Tube drainage and mechanical 
ventilation duration, ICU LOS, and Hospital LOS were used as measures of 
efficacy and were compared between tPA and surgical intervention [Table 4.]. 
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RESULTS 
 
PREDICTORS OF RETAINED HEMOTHORAX 
 Early identification of retained hemothorax is pivotal for developing and 
implementing a treatment plan before life-threatening and potentially irreversible 
complications such as empyema, pneumonia, fibrothorax, and respiratory 
compromise develop. Demographic data including patient gender, race, and 
ethnicity were analyzed to determine if certain groups were more prone to 
developing a retained hemothorax. Additionally, injury data was evaluated to 
determine if specific mechanisms of injury or injury types correlate with a higher 
incidence of retained hemothorax. Injury data included mechanism of injury, and 
the presence or absence of multisystem trauma, rib fracture, pulmonary contusion, 
flail chest, disruption or psuedoanurysm of the aorta or other great vessel, 
respiratory failure and/or tissue specific injuries (brain, spine, lung, heart, 
diaphragm, vessel, esophagus, spleen, liver, kidney, pelvis, extremity, or other 
orthopedic injury). 
 The data indicate that there is no statistically significant correlation between 
the development of RH and patient gender, race, or ethnicity. Additionally, injury 
data revealed no statistically significant correlation between the development of 
RH and the presence of multisystem trauma, brain injury, spinal injury, lung injury, 
heart injury, diaphragm injury, vascular injury, disruption or pseudoaneurysm of 
the aorta or great vessel, respiratory failure, respiratory failure within 4 hours of 
injury, esophageal injury, spleen injury, liver injury, kidney injury, pelvic injury, 
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orthopedic injury, rib fracture, flail chest, pulmonary contusion, or mechanism of 
injury. This test, however, did reveal statistically significant relationships between 
the development of RH and abdominal and extremity injuries respectively at α = 
0.05. 
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Table 1. Demographic and Injury Factors Indicating Pre-Disposition to 
Retained Hemothorax 
 
 
 
Retained 
Hemothorax 
Total Sig. No Yes 
 
Total 
Count 100 16 116   
Expected 
Count 
100.0 16.0 116.0 
 
Gender of 
Patient 
Female Count 19 2 21 
.733b 
Expected 
Count 
18.1 2.9 21.0 
Male Count 81 14 95 
Expected 
Count 
81.9 13.1 95.0 
Race White Count 47 5 52 
.490a 
Expected 
Count 
44.8 7.2 52.0 
Black or 
African 
American 
Count 40 8 48 
Expected 
Count 
41.4 6.6 48.0 
Other Race Count 13 3 16 
Expected 
Count 
13.8 2.2 16.0 
Ethnicity Hispanic or 
Latino 
Count 11 3 14 
.408b 
Expected 
Count 
12.1 1.9 14.0 
Not 
Hispanic or 
Latino 
Count 89 13 102 
Expected 
Count 
87.9 14.1 102.0 
Mechanism 
of Injury 
Blunt Count 50 6 56 
.353a 
Expected 
Count 
48.3 7.7 56.0 
Penetrating Count 50 10 60 
Expected 
Count 
51.7 8.3 60.0 
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Multisystem 
Trauma 
No Count 45 8 53 
.709a 
Expected 
Count 
45.7 7.3 53.0 
Yes Count 55 8 63 
Expected 
Count 
54.3 8.7 63.0 
Brain Injury No Count 88 16 104 
.214b 
Expected 
Count 
89.7 14.3 104.0 
Yes Count 12 0 12 
Expected 
Count 
10.3 1.7 12.0 
Spinal Injury No Count 73 12 85 
1.000b 
Expected 
Count 
73.3 11.7 85.0 
Yes Count 27 4 31 
Expected 
Count 
26.7 4.3 31.0 
Lung Injury No Count 28 5 33 
.772b 
Expected 
Count 
28.4 4.6 33.0 
Yes Count 72 11 83 
Expected 
Count 
71.6 11.4 83.0 
Heart Injury No Count 84 15 99 
.461b 
Expected 
Count 
85.3 13.7 99.0 
Yes Count 16 1 17 
Expected 
Count 
14.7 2.3 17.0 
Diaphragm 
Injury 
No Count 83 10 93 
.086b 
Expected 
Count 
80.2 12.8 93.0 
Yes Count 17 6 23 
Expected 
Count 
19.8 3.2 23.0 
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Vascular 
Injury 
No Count 84 14 98 
1.000b 
Expected 
Count 
84.5 13.5 98.0 
Yes Count 16 2 18 
Expected 
Count 
15.5 2.5 18.0 
 Disruption or 
Pseudoaneur
ysm of Aorta 
or Great 
Vessel 
No Count 93 14 107 
.609b 
Expected 
Count 
92.2 14.8 107.0 
Yes Count 7 2 9 
Expected 
Count 
7.8 1.2 9.0 
Respiratory 
Failure 
No Count 86 12 98 
.271b 
Expected 
Count 
84.5 13.5 98.0 
Yes Count 14 4 18 
Expected 
Count 
15.5 2.5 18.0 
Respiratory 
Failure 
Within 4 
Hours 
No Count 91 16 107 
.357b 
Expected 
Count 
92.2 14.8 107.0 
Yes Count 9 0 9 
Expected 
Count 
7.8 1.2 9.0 
Esophageal 
Injury 
No Count 98 16 114 
1.000b 
Expected 
Count 
98.3 15.7 114.0 
Yes Count 2 0 2 
Expected 
Count 
1.7 .3 2.0 
Spleen Injury No Count 87 14 101 
1.000b 
Expected 
Count 
87.1 13.9 101.0 
Yes Count 13 2 15 
Expected 
Count 
12.9 2.1 15.0 
 27 
Liver Injury No Count 76 10 86 
.355b 
Expected 
Count 
74.1 11.9 86.0 
Yes Count 24 6 30 
Expected 
Count 
25.9 4.1 30.0 
Abdominal 
Alimentary 
Tract Injury 
No Count 92 11 103 
.017b 
Expected 
Count 
88.8 14.2 103.0 
Yes Count 8 5 13 
Expected 
Count 
11.2 1.8 13.0 
Kidney Injury No Count 91 14 105 
.648b 
Expected 
Count 
90.5 14.5 105.0 
Yes Count 9 2 11 
Expected 
Count 
9.5 1.5 11.0 
Pelvic Injury No Count 89 15 104 
1.000b 
Expected 
Count 
89.7 14.3 104.0 
Yes Count 11 1 12 
Expected 
Count 
10.3 1.7 12.0 
Other 
Orthopedic 
Injury 
No Count 53 12 65 
.100a 
Expected 
Count 
56.0 9.0 65.0 
Yes Count 47 4 51 
Expected 
Count 
44.0 7.0 51.0 
Extremity 
Injury 
No Count 53 13 66 
.034a 
Expected 
Count 
56.9 9.1 66.0 
Yes Count 47 3 50 
Expected 
Count 
43.1 6.9 50.0 
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Rib Fracture No Count 32 3 35 
.385b 
Expected 
Count 
30.2 4.8 35.0 
Yes Count 68 13 81 
Expected 
Count 
69.8 11.2 81.0 
Number of 
Rib Fractures 
0 Count 33 3 36 
.219c 
Expected 
Count 
31.0 5.0 36.0 
1-5 Count 43 11 54 
Expected 
Count 
46.6 7.4 54.0 
6-10 Count 20 2 22 
Expected 
Count 
19.0 3.0 22.0 
11+ Count 4 0 4 
Expected 
Count 
3.4 .6 4.0 
Flail Chest No Count 90 14 104 
.671b 
Expected 
Count 
89.7 14.3 104.0 
Yes Count 10 2 12 
Expected 
Count 
10.3 1.7 12.0 
Pulmonary 
Contusion 
No Count 39 6 45 
.909a 
Expected 
Count 
38.8 6.2 45.0 
Yes Count 61 10 71 
Expected 
Count 
61.2 9.8 71.0 
 
Measure of Significance: 
a. Pearson Chi-Square 
b. Fisher’s Exact Test 
c. Likelihood Ratio 
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SAFETY OF tPA 
The first step in critically evaluating the potential application of tissue 
plasminogen activator as a pharmaceutical alternative therapy for retained 
hemothorax is establishing the safety of its intrapleural application. The incidence 
of complications including post-trauma infection (verified by positive sputum and/or 
blood sample), empyema, or mortality were compared between RH patients that 
received tPA and RH patients that did not receive tPA.  
No statistically significant difference in post-trauma infection, sputum 
culture, blood culture, or empyema was found between tPA and non-tPA patients. 
tPA treatment was associated with a statistically significant reduction in mortality, 
however, there was only one such case. 
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Table 2. Safety of Tissue Plasminogen Activator  
 
 
(Descriptive Statistics) 
 
 tPA 
Administered Mean 
Std. 
Deviation N 
Post-Trauma 
Infection 
No .40 .548 5 
Yes .40 .507 15 
Total .40 .503 20 
Positive Sputum 
Culture 
No .20 .447 5 
Yes .27 .458 15 
Total .25 .444 20 
Positive Blood 
Culture 
No .20 .447 5 
Yes .07 .258 15 
Total .10 .308 20 
Empyema No .20 .447 5 
Yes .13 .352 15 
Total .15 .366 20 
Mortality No .20 .447 5 
Yes .00 .000 15 
Total .05 .224 20 
 
(Levene's Test of Equality of Error Variancesa) 
 
 F df1 df2 Sig. 
Post-Trauma 
Infection 
.000 1 18 1.000 
Positive Sputum 
Culture 
.368 1 18 .552 
Positive Blood 
Culture 
2.610 1 18 .124 
Empyema .437 1 18 .517 
Mortality 24.000 1 18 .000 
Tests the null hypothesis that the error variance of the 
dependent variable is equal across groups. 
a. Design: Intercept + tPA 
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OUTCOMES OF RETAINED HEMOTHORAX PATIENTS 
 Between July 2013 and December 2016, 14 patients that presented to the 
BMC ED with a pneumohemothorax and developed a subsequent retained 
hemothorax were treated with intrapleural tPA. This patient sample had a mean 
age of 38 years and was majority male (11 of 14, 79%). Approximately two-thirds 
experienced penetrating injuries (9 of 14, 64%) with the other one-third 
experiencing a blunt mechanism of injury (5 of 14, 36%). These patients received 
on average 3 doses of tPA (range 1-6) with a 30 mg. mean total dose. Of the 14 
patients treated with tPA, 6 had successful resolution of RH (43%), while 7 required 
VATS as a definitive intervention for RH resolution. One patient experienced a 
systemic reaction to tPA causing a major bleeding complication from splenic 
hemorrhage and required additional intervention beyond VATS. 
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Table 3. Outcomes of Retained Hemothorax Patients Treated with tPA 
and/or VATS Between July 2013 and December 2016 
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EFFICACY OF tPA 
Prior studies have determined that thoracotomy and VATS are highly 
successful definitive treatments for RH. These interventions, however, are highly 
invasive and associated with high morbidity and mortality. Intrapleural tPA may 
serve as a minimally invasive alternative but its efficacy in treating RH has yet to 
be established. Patients that saw successful definitive resolution of RH with tPA 
were compared to those that required surgery for definitive resolution of RH. 
Individuals that received tPA but required subsequent surgical intervention were 
grouped with individuals that received surgery alone because in both instances, 
surgery served as the definitive intervention. Outcome measures including tube 
drainage and ventilator duration, ICU LOS, and hospital LOS were used as 
comparative efficacy measures.  
 This analysis revealed no statistically significant difference between tPA 
and surgery for tube drainage duration, ICU LOS, or hospital LOS. Definitive 
treatment with tPA was, however, associated with a statistically significant 
decrease in mechanical ventilation time.   
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Table 4. Efficacy of Tissue Plasminogen Activator 
 
 
(Descriptive Statistics) 
 
 
Definitive Intervention Mean 
Std. 
Deviation N 
Tube Drainage 
Time 
tPA 12.25 3.919 8 
Surgery 14.70 5.143 10 
Total 13.61 4.680 18 
Ventilator Time tPA 4.38 6.989 8 
Surgery 1.50 1.900 10 
Total 2.78 4.918 18 
ICU LOS tPA 6.00 9.592 8 
Surgery 5.50 5.233 10 
Total 5.72 7.242 18 
Hospital LOS tPA 22.88 13.851 8 
Surgery 19.80 10.272 10 
Total 21.17 11.719 18 
 
(Levene's Test of Equality of Error Variancesa) 
 
 F df1 df2 Sig. 
Tube Drainage 
Time 
.032 1 16 .860 
Ventilator Time 11.028 1 16 .004 
ICU LOS 3.106 1 16 .097 
Hospital LOS 2.577 1 16 .128 
Tests the null hypothesis that the error variance of the 
dependent variable is equal across groups. 
a. Design: Intercept + Definitive Intervention 
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PREDICTORS OF tPA SUCCESS 
 The same demographic and injury data from the predictors of RH study 
were analyzed to elucidate characteristics which may serve to predict the success 
of tPA as a definitive intervention. Patients that saw successful definitive resolution 
of RH with tPA were compared to those that required surgery for definitive 
resolution of RH. Again, individuals that received tPA but required subsequent 
surgical intervention were grouped with individuals that received surgery alone 
because in both instances, surgery served as the definitive intervention. No 
patients in this sample presented with brain injury, esophageal injury, flail chest, or 
respiratory failure within 4 hours. 
 No statistically significant correlation was found between any demographic 
or injury factors and the success of tPA as a definitive treatment. Each injury type 
is equally common between individuals that were definitively treated with tPA and 
those that were definitively treated with surgery. Thus, no demographic nor injury 
characteristics evaluated in this study could be used to predict the success of tPA 
as a definitive intervention.  
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Table 5. Demographic and Injury Factors Indicating Potential Candidates 
for tPA Administration 
 
 
 
Definitive 
Intervention 
Total Sig. tPA Surgery 
 
Total 
Count 8 10 18  
Expected 
Count 
8.0 10.0 18.0 
Gender of 
Patient 
Female Count 1 3 4 
.588b 
Expected 
Count 
1.8 2.2 4.0 
Male Count 7 7 14 
Expected 
Count 
6.2 7.8 14.0 
Race White Count 0 4 4 
.056c 
Expected 
Count 
1.8 2.2 4.0 
Black or 
African 
American 
Count 6 5 11 
Expected 
Count 
4.9 6.1 11.0 
Other Race Count 2 1 3 
Expected 
Count 
1.3 1.7 3.0 
Ethnicity Hispanic or 
Latino 
Count 2 1 3 
.559b 
Expected 
Count 
1.3 1.7 3.0 
Not 
Hispanic or 
Latino 
Count 6 9 15 
Expected 
Count 
6.7 8.3 15.0 
Mechanism 
of Injury 
Blunt Count 2 3 5 
1.000b 
Expected 
Count 
2.2 2.8 5.0 
Penetrating Count 6 7 13 
Expected 
Count 
5.8 7.2 13.0 
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Multisystem 
Trauma 
No Count 5 4 9 
.637b 
Expected 
Count 
4.0 5.0 9.0 
Yes Count 3 6 9 
Expected 
Count 
4.0 5.0 9.0 
Spinal Injury No Count 5 7 12 
1.000b 
Expected 
Count 
5.3 6.7 12.0 
Yes Count 3 3 6 
Expected 
Count 
2.7 3.3 6.0 
Lung Injury No Count 3 2 5 
.608b 
Expected 
Count 
2.2 2.8 5.0 
Yes Count 5 8 13 
Expected 
Count 
5.8 7.2 13.0 
Heart Injury No Count 7 10 17 
.444b 
Expected 
Count 
7.6 9.4 17.0 
Yes Count 1 0 1 
Expected 
Count 
.4 .6 1.0 
Diaphragm 
Injury 
No Count 6 7 13 
1.000b 
Expected 
Count 
5.8 7.2 13.0 
Yes Count 2 3 5 
Expected 
Count 
2.2 2.8 5.0 
Vascular 
Injury 
No Count 8 7 15 
.216b 
Expected 
Count 
6.7 8.3 15.0 
Yes Count 0 3 3 
Expected 
Count 
1.3 1.7 3.0 
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 Disruption or 
Pseudoaneur
ysm of Aorta 
or Great 
Vessel 
No Count 7 8 15 
1.000b 
Expected 
Count 
6.7 8.3 15.0 
Yes Count 1 2 3 
Expected 
Count 
1.3 1.7 3.0 
Respiratory 
Failure 
No Count 6 8 14 
1.000b 
Expected 
Count 
6.2 7.8 14.0 
Yes Count 2 2 4 
Expected 
Count 
1.8 2.2 4.0 
Spleen Injury No Count 8 9 17 
1.000b 
Expected 
Count 
7.6 9.4 17.0 
Yes Count 0 1 1 
Expected 
Count 
.4 .6 1.0 
Liver Injury No Count 5 6 11 
1.000b 
Expected 
Count 
4.9 6.1 11.0 
Yes Count 3 4 7 
Expected 
Count 
3.1 3.9 7.0 
Abdominal 
Alimentary 
Tract Injury 
No Count 5 7 12 
1.000b 
Expected 
Count 
5.3 6.7 12.0 
Yes Count 3 3 6 
Expected 
Count 
2.7 3.3 6.0 
Kidney Injury No Count 8 9 17 
1.000b 
Expected 
Count 
7.6 9.4 17.0 
Yes Count 0 1 1 
Expected 
Count 
.4 .6 1.0 
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Pelvic Injury No Count 7 10 17 
.444b 
Expected 
Count 
7.6 9.4 17.0 
Yes Count 1 0 1 
Expected 
Count 
.4 .6 1.0 
Other 
Orthopedic 
Injury 
No Count 5 8 13 
.608b 
Expected 
Count 
5.8 7.2 13.0 
Yes Count 3 2 5 
Expected 
Count 
2.2 2.8 5.0 
Extremity 
Injury 
No Count 5 9 14 
.275b 
Expected 
Count 
6.2 7.8 14.0 
Yes Count 3 1 4 
Expected 
Count 
1.8 2.2 4.0 
Rib Fracture No Count 2 2 4 
1.000b 
Expected 
Count 
1.8 2.2 4.0 
Yes Count 6 8 14 
Expected 
Count 
6.2 7.8 14.0 
Number of 
Rib Fractures 
0 Count 2 2 4 
.538c 
Expected 
Count 
1.8 2.2 4.0 
1-5 Count 6 7 13 
Expected 
Count 
5.8 7.2 13.0 
6-10 Count 0 1 1 
Expected 
Count 
.4 .6 1.0 
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Pulmonary 
Contusion 
No Count 3 3 6 
1.000b 
Expected 
Count 
2.7 3.3 6.0 
Yes Count 5 7 12 
Expected 
Count 
5.3 6.7 12.0 
 
Measure of Significance: 
a. Pearson Chi-Square 
b. Fisher’s Exact Test 
c. Likelihood Ratio 
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DISCUSSION 
 
With prior studies demonstrating an incidence of RH between 5 and 30% it 
is apparent that the true incidence of this pathology is yet unknown (Heniford et al. 
1997, Menger et al. 2012). Since early diagnosis of RH is imperative for timely 
intervention and the prevention of complications, the identification of factors that 
could serve as early indicators for the development of RH could help prompt early 
preventative measures. The patient sample of the present study consisted of 116 
patients with a pneumohemothorax, 16 of which developed a subsequent retained 
hemothorax, an incidence of 13.8%. Among the demographic and injury variables 
tested, abdominal and extremity injuries showed a statistically significant 
correlation with the development of RH indicating that these injuries may serve as 
predictive factors [Table 1.]. The association between extremity injury and RH is 
unclear, however injury to the extremity may be simply be associated with more 
severe trauma. With the proximity of the abdominal cavity to the thoracic cavity, 
injury to this area may be associated with more severe frontal trauma and 
additional injuries to the proximal thorax, requiring more complicated 
management. Additionally, although not statistically significant, patients that 
developed a retained hemothorax were more likely to have a diaphragmic injury. 
If the diaphragm is disrupted, additional blood from the thorax may infiltrate the 
pleural space and increase the size of the hemothorax. It is possible that in some 
patients with abdominal injuries (e.g. bowel perforations), blood may have 
collected around the diaphragm, obscured the diaphragm on radiologic images, 
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and allowed for small diaphragmic disruptions with leaking into the pleural space 
to go undiagnosed.  
To determine the safety of intrapleural tPA, the complication rates among 
RH patients were compared between those who received tPA and those who did 
not (tube thoracostomy, VATS, thoracotomy only). No statistically significant 
difference in the rates of post-trauma infection, positive sputum cultures, positive 
blood cultures, or empyema were found between the two treatment groups 
suggesting that tPA is equally safe as other interventions in terms of infection. tPA 
treatment was associated with a statistically significant decrease in mortality, 
however, only one such case was observed in which a patient developed 
cardiogenic shock concurrent to his retained hemothorax and expired prior to 
receiving any treatment beyond a tube thoracostomy and this specific demise may 
likely be more attributable to pre-existing cardiac co-morbidity than to any 
particular aspect of trauma management. [Table 3.] 
In the outcomes analysis, 14 cases of RH patients treated with tPA at BMC 
were evaluated to determine the rate of success of intrapleural tPA. Among the 14 
patients, only 6 had successful resolution of their RH with tPA. This 43% success 
rate is far lower than that of other studies that demonstrated 91-94% rates of 
success for RH resolution with intrapleural fibrinolytics (Moulton et al. 1989, Jerjes-
Sanchez et al. 1996, Iuci et al. 1998, Kimbrell et al. 2007). Additionally, one patient 
experienced a major adverse systemic reaction in which tPA was absorbed 
systemically and exacerbated hemorrhage from a splenic laceration [Table 3.]. 
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With the intrapleural administration of tPA, it is expected that the drug will act 
locally within the pleural space, however, this outcome calls the safety of this route 
into question. Other interventions such as VATS and thoracotomy are associated 
with significant risk and if further investigations demonstrate that the incidence of 
systemic tPA reactions is sufficiently low, then tPA may still prove to be a far safer 
alternative.  
In the efficacy analysis, RH patients that had definitive RH resolution with 
tPA were compared to patients that required surgery for the definitive resolution of 
RH (including individuals who received tPA but required subsequent surgery and 
individuals who underwent surgery without prior tPA intervention). Outcome 
measures including tube drainage time, mechanical ventilator time, ICU LOS, and 
hospital LOS were used to evaluate the difference in patient burden between the 
two treatment groups (e.g. patient cost, time in hospital, chance of developing 
complications, etc.). Results from this study showed no significant difference in 
tube drainage time, ICU LOS, or hospital LOS. These data did, however, 
demonstrate that tPA as a definitive RH treatment is associated with a statistically 
significant decrease in mechanical ventilation time. Each day spent on a ventilator 
is associated with a 3% increase in the chance of developing ventilator-associated 
pneumonia (VAP) and since VAP has been cited to have a mortality rate between 
33 and 50%, reduced ventilation time is associated with a significantly improved 
patient prognosis (Weinstein et al. & American Thoracic Society). 
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The final analysis, examining potential predictors of tPA success, aimed to 
identify demographic or injury variables that could be used to predict if tPA will be 
successful as a definitive RH intervention. As in the previous study, patients with 
successful resolution of RH with tPA were compared to patients that required 
surgery for RH resolution. No patients in this sample presented with a brain injury, 
esophageal injury, flail chest, or respiratory failure within 4 hours of injury, so the 
predictive capacity of these variables was unable to be studied. Additionally, no 
statistically significant relationship was found between any demographic or injury 
factors and definitive treatment, indicating that none of these variables could be 
used to predict the success of definitive tPA treatment. Since the patient sample 
size of this study was small, further investigation with a larger sample size may 
reveal significant differences between the two treatment groups not found in the 
present study. 
In conclusion, intrapleural tPA is a safe alternative to surgical intervention 
in the treatment of RH. Rates of complications were not significantly different 
between patients treated definitively with tPA and surgery suggesting that both 
interventions carry a similar risk of infection. Since surgery is more invasive, it 
carries a higher risk of mortality and further study is needed to confirm the reduced 
mortality rate associated with fibrinolytic therapy. tPA also proved to be efficacious 
in resolving retained hemothorax, however its efficacy may be significantly less 
than that reported in prior studies. tPA administration was associated with a lower 
mechanical ventilation time in our single-institution retrospective review, which 
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may correlate with improved patient prognosis and decreased patient burden. 
Although 7 out of 14 patients in the outcomes study required VATS after tPA failed 
to resolve RH, the decrease in ventilator-associated pneumonia associated with 
tPA may be worth the risk of failed intervention and the longer hospital stay that 
comes with multiple interventions. With these outcomes in mind, tPA should be 
considered prior to surgery in the RH treatment algorithm to potentially prevent the 
need for invasive procedures which carry higher morbidity, mortality, and patient 
cost, and to decrease the chance of developing a VAP. Patients undergoing tPA 
regimens should be continually evaluated for improvement of symptoms and if RH 
size is unchanged or increased, video-assisted thoracoscopic surgery should be 
considered as a definitive secondary measure. 
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APPENDIX 
 
Data Collection Form – Outcomes of Management of Retained Hemothorax 
Study ID: ________ DOB: __________________ 
Race/Ethnicity: __________________________ 
Date of admission: __________    Date of Discharge: ____________    
Mechanism:    Blunt  |  Penetrating 
Age: ______  Gender:  M  |  F ISS: _______Admission GCS: ______ 
Injuries: 
________________________________________________________________
______________ 
Multisystem trauma:  Y  |  N  
Brain injury:  Y  |  N   
Spinal injury:  Y  |  N 
Lung injury:  Y  |  N   
Heart injury:  Y  |  N   
Diaphragm injury:  Y  |  N 
Vascular injury:  Y  |  N      
Disruption/pseudoaneurysm of great vessel or aorta:  Y  |  N 
Respiratory failure:  Y  |  N   If yes, respiratory failure within 4 hours?  Y  |  N 
Esophageal injury:  Y  |  N   
Spleen injury:  Y  |  N 
Liver injury:  Y  |  N  
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Abdominal alimentary tract injury:  Y  |  N  
Kidney injury:  Y  |  N 
Pelvic injury:  Y  |  N  
Other orthopedic injury:  Y  |  N   
Extremity injury:  Y  |  N 
AIS Head: _____ AIS Thoracic: _____ AIS Abdomen: _____  
AIS Extremity: _____ 
Rib fractures:  Y  |  N    If yes, # of rib fractures: ______     Flail?  Y  |  N     
Pulmonary contusion?  Y  |  N  
Chest tube placed?  Y  |  N    If yes:   
Provider:  ED resident  |  Surgery resident  |  IR provider 
Position:  Anterior  |  Posterior  |  Apical |  Basal   
Size:  28 Fr  |  32 Fr  |  36 Fr  |  Pigtail  |  Other: ______ 
Hemodynamically unstable requiring OR?  Y  |  N  
>1500 cc initial drainage requiring OR?  Y  |  N 
# Chest tubes placed: ___   
If 2nd tube: Provider:  ED resident  |  Surgery resident  |  IR provider 
Position:  Anterior  |  Posterior  |  Apical |  Basal   
Size:  28 Fr  |  32 Fr  |  36 Fr  |  Pigtail  |  Other: ______ 
Hospital day of tube #1: _____   Hospital day of tube #2: ______ 
More than 2 chest tubes?  Y  |  N 
Retained hemothorax?  Y  |  N 
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TPA?  Y  |  N    If yes:  Doses of TPA:  ____  
Frequency of administration of TPA: ________________ 
Operative intervention?  Y  |  N    If yes, days from injury to OR: 
_______________________________ 
Procedure:  VATS  |  Thoracotomy  
Bronchoscopy:  Y  |  N     
Evacuation rHTX:  Y  |  N 
Decortication:  Y  |  N       
# of Intra-op tubes placed:  _____ straight   _____ angled 
Days with post-op air leak: _____ 
Post-op tube drainage days:  _____   
Total tube drainage days: _____ 
Post-op vent days: _____    
Total vent days: _____ 
Post-op ICU days: _____    
Total ICU days: _____ 
Hospital LOS: _____ 
Complications:  Y  |  N   If yes, describe: 
__________________________________________________ 
Post-trauma infection?  Y  |  N   If yes:   
(+) Sputum Cx?  Y  |  N 
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(+) Blood Cx?  Y  |  N 
(+) Empyema?  Y  |  N 
Mortality?  Y  |  N 
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